TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. - PE Ratioverified

RNAZ

Price:

$4.7

Market Cap:

$4.47M

TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agen...[Read more]

Industry

Biotechnology

IPO Date

2021-07-08

Stock Exchange

NASDAQ

Ticker

RNAZ

The PE Ratio as of June 2026 (TTM) for TransCode Therapeutics, Inc. (RNAZ) is -1.27

According to TransCode Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.27. This represents a change of 385.18% compared to the average of -0.26 of the last 4 quarters.

TransCode Therapeutics, Inc. (RNAZ) Historical PE Ratio (quarterly & annually)

How has RNAZ PE Ratio performed in the past?

The mean historical PE Ratio of TransCode Therapeutics, Inc. over the last ten years is -6316.44. The current -1.27 PE Ratio has changed -97.99% with respect to the historical average. Over the past ten years (40 quarters), RNAZ's PE Ratio was at its highest in in the June 2021 quarter at 3.69K. The PE Ratio was at its lowest in in the March 2020 quarter at -285131.00.

Quarterly (TTM)
Annual

Average

-6316.44

Median

-582.53

Minimum

-38017.47

Maximum

-0.13

TransCode Therapeutics, Inc. (RNAZ) PE Ratio by Quarter and Year

Discovering the peaks and valleys of TransCode Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 3.18%

Maximum Annual PE Ratio = -0.13

Minimum Annual Increase = -99.77%

Minimum Annual PE Ratio = -38017.47

Quarterly (TTM)
Annual
YearPE RatioChange
2025-0.13-90.74%
2024-1.4013.51%
2023-1.23-74.05%
2022-4.76-99.77%
2021-2028.24-78.23%
2020-9318.01-75.49%
2019-38017.473.18%

TransCode Therapeutics, Inc. (RNAZ) Average PE Ratio

How has RNAZ PE Ratio performed in the past?

The current PE Ratio of TransCode Therapeutics, Inc. (RNAZ) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-0.92

5-year avg

-407.15

10-year avg

-6316.44

TransCode Therapeutics, Inc. (RNAZ) PE Ratio vs. Peers

How is RNAZ’s PE Ratio compared to its peers?

TransCode Therapeutics, Inc.’s PE Ratio is less than IN8bio, Inc. (-0.38), less than Lyra Therapeutics, Inc. (-0.02), less than Aptevo Therapeutics Inc. (-0.01), less than Galecto, Inc. (-0.12), less than Phio Pharmaceuticals Corp. (-0.72), less than HCW Biologics Inc. (-0.13), less than Kiora Pharmaceuticals, Inc. (-0.95), less than Aprea Therapeutics, Inc. (-0.41), less than Bolt Biotherapeutics, Inc. (-0.25), less than Acurx Pharmaceuticals, Inc. (-0.31),

Build a custom stock screener for TransCode Therapeutics, Inc. (RNAZ) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like TransCode Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

TransCode Therapeutics, Inc. (RNAZ) and other stocks custom spreadsheet templates

The easiest way to analyze a company like TransCode Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is TransCode Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for TransCode Therapeutics, Inc. (RNAZ)?

What is the highest PE Ratio for TransCode Therapeutics, Inc. (RNAZ)?

What is the 3-year average PE Ratio for TransCode Therapeutics, Inc. (RNAZ)?

What is the 5-year average PE Ratio for TransCode Therapeutics, Inc. (RNAZ)?

How does the current PE Ratio for TransCode Therapeutics, Inc. (RNAZ) compare to its historical average?